| scholarly article | Q13442814 |
| P2093 | author name string | Ellen Sidransky | |
| Ozlem Goker-Alpan | |||
| Benoit I. Giasson | |||
| Barbara K. Stubblefield | |||
| P2860 | cites work | Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. | Q24634577 |
| Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease | Q24656668 | ||
| Mutation in the alpha-synuclein gene identified in families with Parkinson's disease | Q27860459 | ||
| α-Synuclein in Lewy bodies | Q27860680 | ||
| Staging of brain pathology related to sporadic Parkinson's disease | Q28131702 | ||
| Alpha-synuclein and neurodegenerative diseases | Q28204386 | ||
| Glucocerebrosidase mutations in subjects with parkinsonism | Q28239212 | ||
| Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy | Q29614178 | ||
| Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium | Q29614409 | ||
| Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases | Q29614910 | ||
| Glucocerebrosidase mutations in Chinese subjects from Taiwan with sporadic Parkinson disease | Q30483458 | ||
| Double immunolabeling of neuropeptides in the human hypothalamus as analyzed by confocal laser scanning fluorescence microscopy | Q31934009 | ||
| Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews | Q34365028 | ||
| Lewy bodies | Q34478663 | ||
| Mutations for Gaucher disease confer high susceptibility to Parkinson disease | Q34607524 | ||
| Parkinsonism among Gaucher disease carriers | Q35444509 | ||
| Alpha-synuclein: normal function and role in neurodegenerative diseases. | Q35749928 | ||
| Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies | Q35764504 | ||
| Lipid composition of microdomains is altered in a cell model of Gaucher disease | Q36745037 | ||
| The spectrum of parkinsonian manifestations associated with glucocerebrosidase mutations | Q37068884 | ||
| Mutations in GBA are associated with familial Parkinson disease susceptibility and age at onset | Q37180477 | ||
| Complete screening for glucocerebrosidase mutations in Parkinson disease patients from Portugal | Q37330617 | ||
| Association of glucocerebrosidase mutations with dementia with lewy bodies | Q37379711 | ||
| Immunohistochemical and biochemical studies demonstrate a distinct profile of alpha-synuclein permutations in multiple system atrophy | Q42493792 | ||
| Glucosylsphingosine accumulation in tissues from patients with Gaucher disease: correlation with phenotype and genotype | Q44123131 | ||
| Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism? | Q44479792 | ||
| Neuropathology provides clues to the pathophysiology of Gaucher disease | Q47247270 | ||
| Glucocerebrosidase mutations are an important risk factor for Lewy body disorders | Q48491146 | ||
| Genotypic Heterogeneity and Phenotypic Variation among Patients with Type 2 Gaucher's Disease | Q51994501 | ||
| Analysis of the glucocerebrosidase gene in Parkinson's disease | Q57318911 | ||
| In situ and in vitro study of colocalization and segregation of alpha-synuclein, ubiquitin, and lipids in Lewy bodies | Q64764806 | ||
| Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset | Q81147302 | ||
| Association of alpha-synuclein and mutants with lipid membranes: spin-label ESR and polarized IR | Q82740960 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Synuclein | Q24767155 |
| P304 | page(s) | 641-649 | |
| P577 | publication date | 2010-09-14 | |
| P1433 | published in | Acta Neuropathologica | Q343168 |
| P1476 | title | Glucocerebrosidase is present in α-synuclein inclusions in Lewy body disorders | |
| P478 | volume | 120 |
| Q48278741 | 100 years of Lewy pathology |
| Q55361950 | 3,4-Dihydroxyphenylacetaldehyde-Induced Protein Modifications and Their Mitigation by N-Acetylcysteine. |
| Q37096051 | A New Glucocerebrosidase Chaperone Reduces α-Synuclein and Glycolipid Levels in iPSC-Derived Dopaminergic Neurons from Patients with Gaucher Disease and Parkinsonism |
| Q37346468 | A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies |
| Q41948332 | A twelve-year follow-up study on a case of early-onset parkinsonism preceding clinical manifestation of Gaucher disease |
| Q41871999 | Accumulation and distribution of α-synuclein and ubiquitin in the CNS of Gaucher disease mouse models |
| Q35960402 | Aggregation of α-synuclein in brain samples from subjects with glucocerebrosidase mutations |
| Q28308084 | Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells |
| Q37968014 | Autosomal dominant Parkinsonism: its etiologies and differential diagnoses |
| Q35122963 | CNS expression of glucocerebrosidase corrects alpha-synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathy |
| Q38825497 | Cerebrospinal fluid biomarkers in Alzheimer's and Parkinson's diseases-From pathophysiology to clinical practice |
| Q48824358 | Cerebrospinal fluid fatty acids in glucocerebrosidase-associated Parkinson's disease |
| Q92590277 | Characterization of the visceral and neuronal phenotype of 4L/PS-NA mice modeling Gaucher disease |
| Q53325232 | Clinical characteristics of the neurological forms of Gaucher's disease |
| Q45245196 | Clinical, genetic, and brain sonographic features related to Parkinson's disease in Gaucher disease |
| Q45326771 | Commentary on “Pilot study using ambroxol as a pharmacological chaperone in type 1 Gaucher disease” by Zimran et al |
| Q34238616 | Development of targeted therapies for Parkinson's disease and related synucleinopathies |
| Q39366291 | Discovery, validation and optimization of cerebrospinal fluid biomarkers for use in Parkinson's disease. |
| Q52689754 | Dysregulation of the autophagic-lysosomal pathway in Gaucher and Parkinson's disease |
| Q35955350 | Exploring the link between glucocerebrosidase mutations and parkinsonism |
| Q89521816 | Fabry Disease With Concomitant Lewy Body Disease |
| Q38595730 | From rare to common and back again: 60years of lysosomal dysfunction. |
| Q38611816 | GBA mutations in Parkinson disease: earlier death but similar neuropathological features. |
| Q57040370 | GBA-Associated Parkinson's Disease and Other Synucleinopathies |
| Q91421330 | GBA1 mutations: Prospects for exosomal biomarkers in α-synuclein pathologies |
| Q27002301 | Gaucher disease and comorbidities: B-cell malignancy and parkinsonism |
| Q35851610 | Gaucher-Associated Parkinsonism |
| Q38237560 | Genetic convergence of Parkinson's disease and lysosomal storage disorders |
| Q27005669 | Glucocerebrosidase and Parkinson disease: Recent advances |
| Q87497276 | Glucocerebrosidase and parkinsonism: lessons to learn |
| Q40196691 | Glucocerebrosidase deficiency in dopaminergic neurons induces microglial activation without neurodegeneration. |
| Q42513965 | Glucocerebrosidase expression patterns in the non-human primate brain. |
| Q38811401 | Glucocerebrosidase in Parkinson's disease: Insights into pathogenesis and prospects for treatment |
| Q38007465 | Glucocerebrosidase involvement in Parkinson disease and other synucleinopathies. |
| Q24337392 | Glucocerebrosidase is shaking up the synucleinopathies |
| Q36389683 | Glucocerebrosidase mutations alter the endoplasmic reticulum and lysosomes in Lewy body disease |
| Q38161987 | Glucocerebrosidase mutations and the pathogenesis of Parkinson disease |
| Q36487922 | Glucocerebrosidase mutations in diffuse Lewy body disease |
| Q48161565 | Glucocerebrosidase mutations influence the natural history of Parkinson's disease in a community-based incident cohort. |
| Q38084062 | Glucocerebrosidase, a new player changing the old rules in Lewy body diseases |
| Q33916685 | Greater risk of parkinsonism associated with non-N370S GBA1 mutations |
| Q38218439 | HDL and cholesterol handling in the brain |
| Q36246469 | Haploinsufficiency of cathepsin D leads to lysosomal dysfunction and promotes cell-to-cell transmission of α-synuclein aggregates |
| Q38588014 | Insights from late-onset familial parkinsonism on the pathogenesis of idiopathic Parkinson's disease |
| Q28588670 | LIMP-2 expression is critical for β-glucocerebrosidase activity and α-synuclein clearance |
| Q36066469 | Loss of P-type ATPase ATP13A2/PARK9 function induces general lysosomal deficiency and leads to Parkinson disease neurodegeneration. |
| Q35152964 | Loss of glucocerebrosidase 1 activity causes lysosomal dysfunction and α-synuclein aggregation |
| Q28118642 | Loss of β-Glucocerebrosidase Activity Does Not Affect Alpha-Synuclein Levels or Lysosomal Function in Neuronal Cells |
| Q89879079 | Lysosomal Ceramide Metabolism Disorders: Implications in Parkinson's Disease |
| Q35858682 | Lysosomal Enzyme Glucocerebrosidase Protects against Aβ1-42 Oligomer-Induced Neurotoxicity |
| Q37461364 | Lysosomal impairment in Parkinson's disease |
| Q89313417 | Lysosomal storage diseases |
| Q37880734 | Lysosomal storage disorders and Parkinson's disease: Gaucher disease and beyond |
| Q38038561 | Lysosome-dependent pathways as a unifying theme in Parkinson's disease. |
| Q34043163 | Lysosomes and α-synuclein form a dangerous duet leading to neuronal cell death. |
| Q38648684 | Membrane lipids as therapeutic targets for Parkinson's disease: a possible link between Lewy pathology and membrane lipids |
| Q36554541 | Membrane-bound α-synuclein interacts with glucocerebrosidase and inhibits enzyme activity. |
| Q37983366 | Mutant GBA1 expression and synucleinopathy risk: first insights from cellular and mouse models. |
| Q28512774 | Neuroinflammation and α-synuclein accumulation in response to glucocerebrosidase deficiency are accompanied by synaptic dysfunction |
| Q47619453 | Neuropathology of genetic synucleinopathies with parkinsonism: Review of the literature |
| Q38905996 | New Directions in Gaucher Disease |
| Q46928589 | No association of GBA mutations and multiple system atrophy. |
| Q38727638 | Parkinson's disease: acid-glucocerebrosidase activity and alpha-synuclein clearance |
| Q37953900 | Pathological looping in the synucleinopathies: investigating the link between Parkinson’s disease and Gaucher disease |
| Q36444517 | Premotor biomarkers for Parkinson's disease - a promising direction of research |
| Q24324577 | Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson's disease |
| Q37324687 | Saposin C protects glucocerebrosidase against α-synuclein inhibition. |
| Q41378010 | Selective imaging of internalized proteopathic α-synuclein seeds in primary neurons reveals mechanistic insight into transmission of synucleinopathies. |
| Q34964902 | Structural features of membrane-bound glucocerebrosidase and α-synuclein probed by neutron reflectometry and fluorescence spectroscopy. |
| Q38118169 | The Association Between ß-Glucocerebrosidase Mutations and Parkinsonism |
| Q26744716 | The Genetic Basis of Cognitive Impairment and Dementia in Parkinson's Disease |
| Q38012653 | The Lewy Body in Parkinson’s Disease and Related Neurodegenerative Disorders |
| Q52848620 | The contribution of mutant GBA to the development of Parkinson disease in Drosophila |
| Q33743729 | The incidence of Parkinsonism in patients with type 1 Gaucher disease: data from the ICGG Gaucher Registry |
| Q34077492 | The link between the GBA gene and parkinsonism |
| Q36124421 | The neurobiology of glucocerebrosidase-associated parkinsonism: a positron emission tomography study of dopamine synthesis and regional cerebral blood flow |
| Q37997386 | The neuropathology of genetic Parkinson's disease |
| Q34336776 | The pallidopyramidal syndromes: nosology, aetiology and pathogenesis |
| Q28077257 | The relationship between glucocerebrosidase mutations and Parkinson disease |
| Q38217376 | The significance of GBA for Parkinson's disease |
| Q28548589 | Visualization of Active Glucocerebrosidase in Rodent Brain with High Spatial Resolution following In Situ Labeling with Fluorescent Activity Based Probes |
| Q48159120 | White matter abnormalities in Parkinson's disease patients with glucocerebrosidase gene mutations |
| Q27321433 | iPSC-derived dopamine neurons reveal differences between monozygotic twins discordant for Parkinson's disease |
| Q48729780 | iPSC-derived neurons from GBA1-associated Parkinson's disease patients show autophagic defects and impaired calcium homeostasis |
| Q35150090 | α-Synuclein Interacts with Glucocerebrosidase Providing a Molecular Link between Parkinson and Gaucher Diseases |
| Q38077665 | α-Synuclein and mitochondrial dysfunction in Parkinson's disease |
| Q36718306 | α-Synuclein oligomers and clinical implications for Parkinson disease |
| Q84539110 | β-Glucocerebrosidase gene mutations in two cohorts of Greek patients with sporadic Parkinson's disease |
Search more.